nodes	percent_of_prediction	percent_of_DWPC	metapath
Clavulanate—Cystitis haemorrhagic—Fludarabine—lymphatic system cancer	0.114	0.114	CcSEcCtD
Clavulanate—Cystitis haemorrhagic—Bleomycin—lymphatic system cancer	0.0838	0.0838	CcSEcCtD
Clavulanate—Induration—Bleomycin—lymphatic system cancer	0.0376	0.0376	CcSEcCtD
Clavulanate—Thrombophlebitis—Mechlorethamine—lymphatic system cancer	0.0297	0.0297	CcSEcCtD
Clavulanate—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.0179	0.0179	CcSEcCtD
Clavulanate—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.0178	0.0178	CcSEcCtD
Clavulanate—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0168	0.0168	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.015	0.015	CcSEcCtD
Clavulanate—Leukopenia—Mechlorethamine—lymphatic system cancer	0.0139	0.0139	CcSEcCtD
Clavulanate—Haemoglobin—Teniposide—lymphatic system cancer	0.0132	0.0132	CcSEcCtD
Clavulanate—Haemorrhage—Teniposide—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Clavulanate—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0126	0.0126	CcSEcCtD
Clavulanate—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.0124	0.0124	CcSEcCtD
Clavulanate—Thrombophlebitis—Carmustine—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Clavulanate—Swelling—Carmustine—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Clavulanate—Haemoglobin—Fludarabine—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Clavulanate—Haemorrhage—Fludarabine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Clavulanate—Swelling—Mitoxantrone—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Clavulanate—Erythema multiforme—Fludarabine—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Clavulanate—Leukopenia—Teniposide—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Clavulanate—Hypokalaemia—Carmustine—lymphatic system cancer	0.0097	0.0097	CcSEcCtD
Clavulanate—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00931	0.00931	CcSEcCtD
Clavulanate—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00912	0.00912	CcSEcCtD
Clavulanate—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00902	0.00902	CcSEcCtD
Clavulanate—Leukopenia—Fludarabine—lymphatic system cancer	0.00898	0.00898	CcSEcCtD
Clavulanate—Pruritus—Mechlorethamine—lymphatic system cancer	0.00894	0.00894	CcSEcCtD
Clavulanate—Convulsion—Fludarabine—lymphatic system cancer	0.00869	0.00869	CcSEcCtD
Clavulanate—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00864	0.00864	CcSEcCtD
Clavulanate—Haemoglobin—Bleomycin—lymphatic system cancer	0.00849	0.00849	CcSEcCtD
Clavulanate—Haemorrhage—Bleomycin—lymphatic system cancer	0.00845	0.00845	CcSEcCtD
Clavulanate—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00818	0.00818	CcSEcCtD
Clavulanate—Vomiting—Mechlorethamine—lymphatic system cancer	0.00803	0.00803	CcSEcCtD
Clavulanate—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00801	0.00801	CcSEcCtD
Clavulanate—Rash—Mechlorethamine—lymphatic system cancer	0.00796	0.00796	CcSEcCtD
Clavulanate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00796	0.00796	CcSEcCtD
Clavulanate—Nausea—Mechlorethamine—lymphatic system cancer	0.0075	0.0075	CcSEcCtD
Clavulanate—Haemoglobin—Carmustine—lymphatic system cancer	0.00741	0.00741	CcSEcCtD
Clavulanate—Urticaria—Teniposide—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Clavulanate—Haemorrhage—Carmustine—lymphatic system cancer	0.00737	0.00737	CcSEcCtD
Clavulanate—Pain—Fludarabine—lymphatic system cancer	0.007	0.007	CcSEcCtD
Clavulanate—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00689	0.00689	CcSEcCtD
Clavulanate—Hypersensitivity—Teniposide—lymphatic system cancer	0.00686	0.00686	CcSEcCtD
Clavulanate—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00685	0.00685	CcSEcCtD
Clavulanate—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00685	0.00685	CcSEcCtD
Clavulanate—Pruritus—Teniposide—lymphatic system cancer	0.00659	0.00659	CcSEcCtD
Clavulanate—Leukopenia—Bleomycin—lymphatic system cancer	0.00658	0.00658	CcSEcCtD
Clavulanate—Diarrhoea—Teniposide—lymphatic system cancer	0.00637	0.00637	CcSEcCtD
Clavulanate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00603	0.00603	CcSEcCtD
Clavulanate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.006	0.006	CcSEcCtD
Clavulanate—Vomiting—Teniposide—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Clavulanate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Clavulanate—Rash—Teniposide—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Clavulanate—Dermatitis—Teniposide—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Clavulanate—Pruritus—Fludarabine—lymphatic system cancer	0.00579	0.00579	CcSEcCtD
Clavulanate—Leukopenia—Carmustine—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Clavulanate—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Clavulanate—Diarrhoea—Fludarabine—lymphatic system cancer	0.0056	0.0056	CcSEcCtD
Clavulanate—Convulsion—Carmustine—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Clavulanate—Nausea—Teniposide—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Clavulanate—Leukopenia—Vincristine—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Clavulanate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00534	0.00534	CcSEcCtD
Clavulanate—Convulsion—Vincristine—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Clavulanate—Vomiting—Fludarabine—lymphatic system cancer	0.0052	0.0052	CcSEcCtD
Clavulanate—Convulsion—Mitoxantrone—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Clavulanate—Rash—Fludarabine—lymphatic system cancer	0.00516	0.00516	CcSEcCtD
Clavulanate—Dermatitis—Fludarabine—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Clavulanate—Pain—Bleomycin—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Clavulanate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Clavulanate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.005	0.005	CcSEcCtD
Clavulanate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Clavulanate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Clavulanate—Nausea—Fludarabine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Clavulanate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Clavulanate—Urticaria—Bleomycin—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Clavulanate—Pain—Carmustine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Clavulanate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Clavulanate—Pain—Vincristine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Clavulanate—Pruritus—Bleomycin—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Clavulanate—Eosinophilia—Methotrexate—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Clavulanate—Pain—Mitoxantrone—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Clavulanate—Urticaria—Mitoxantrone—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Clavulanate—Hypersensitivity—Carmustine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Clavulanate—Vomiting—Bleomycin—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Clavulanate—Rash—Bleomycin—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Clavulanate—Dermatitis—Bleomycin—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Clavulanate—Hypersensitivity—Vincristine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Clavulanate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Clavulanate—Diarrhoea—Carmustine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Clavulanate—Nausea—Bleomycin—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Clavulanate—Haemoglobin—Methotrexate—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Clavulanate—Diarrhoea—Vincristine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Clavulanate—Haemorrhage—Methotrexate—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Clavulanate—Hepatitis—Methotrexate—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Clavulanate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Clavulanate—Vomiting—Carmustine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Clavulanate—Rash—Carmustine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Clavulanate—Dermatitis—Carmustine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Clavulanate—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Clavulanate—Vomiting—Vincristine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Clavulanate—Rash—Vincristine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Clavulanate—Dermatitis—Vincristine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Clavulanate—Nausea—Carmustine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Clavulanate—Vomiting—Mitoxantrone—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Clavulanate—Rash—Mitoxantrone—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Clavulanate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Clavulanate—Nausea—Vincristine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Clavulanate—Nausea—Mitoxantrone—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Clavulanate—Leukopenia—Methotrexate—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Clavulanate—Convulsion—Methotrexate—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Clavulanate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Clavulanate—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Clavulanate—Pain—Methotrexate—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Clavulanate—Urticaria—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Clavulanate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Clavulanate—Pruritus—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Clavulanate—Diarrhoea—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Clavulanate—Vomiting—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Clavulanate—Rash—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Clavulanate—Dermatitis—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Clavulanate—Nausea—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
